KEYNOTE-062:Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

被引：1

作者：

Tabernero, Josep

Bang, Yung-Jue

Fuchs, Charles S.

Ohtsu, Atsushi

Kher, Uma

Lam, Baohoang

Koshiji, Minori

Van Cutsem, Eric

机构：

[1] Vall Hebron Univ Hosp, Barcelona, Spain

[2] Seoul Natl Univ Hosp, Seoul, South Korea

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan

[5] Merck & Co Inc, Kenilworth, NJ USA

[6] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.TPS4138

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4138

引用

页数：2

共 50 条

[1] KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Tabernero, Josep
Bang, Yung-Jue
Fuchs, Charles S.
Ohtsu, Atsushi
Kher, Uma
Lam, Baohoang
Koshiji, Minori
Van Cutsem, Eric
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[2] Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study
Tabernero, J.
Van Cussem, E.
Bang, Y.
Fuchs, C.
Wyrwicz, L.
Lee, K.
Kudaba, I.
Garrido, M.
Chung, C.
Salguero, C. Castro
Mansoor, W.
Braghiroli, M.
Goekkurt, E.
Chao, J.
Wainberg, Z.
Kher, U.
Shah, S.
Karg, S.
Shitara, K.
[J]. ANNALS OF ONCOLOGY, 2019, 30 : 152 - +
[3] Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
Tabernero, Josep
Van Cutsem, Eric
Bang, Yung-Jue
Fuchs, Charles S.
Wyrwicz, Lucjan
Lee, Keun Wook
Kudaba, Iveta
Garrido, Marcelo
Chung, Hyun Cheol
Salguero, Hugo Raul Castro
Mansoor, Wasat
Braghiroli, Maria Ignez Freitas Melro
Goekkurt, Eray
Chao, Joseph
Wainberg, Zev A.
Kher, Uma
Shah, Sukrut
Kang, SoonMo Peter
Shitara, Kohei
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
[4] Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial
Wainberg, Zev A.
Shitara, Kohei
Van Cutsem, Eric
Wyrwicz, Lucjan
Lee, Keun Wook
Kudaba, Iveta
Garrido, Marcelo
Chung, Hyun Cheol Cheol
Lee, Jeeyun
Castro-Salguero, Hugo Raul
Mansoor, Wasat
Braghiroli, Maria Ignez
Karaseva, Nina
Goekkurt, Eray
Satake, Hironaga
Chao, Joseph
Kher, Uma
Shah, Sukrut
Bhagia, Pooja
Tabernero, Josep
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[5] Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Shitara, Kohei
Van Cutsem, Eric
Bang, Yung-Jue
Fuchs, Charles
Wyrwicz, Lucjan
Lee, Keun-Wook
Kudaba, Iveta
Garrido, Marcelo
Chung, Hyun Cheol
Lee, Jeeyun
Castro, Hugo Raul
Mansoor, Wasat
Braghiroli, Maria Ignez
Karaseva, Nina
Caglevic, Christian
Villanueva, Luis
Goekkurt, Eray
Satake, Hironaga
Enzinger, Peter
Alsina, Maria
Benson, Al
Chao, Joseph
Ko, Andrew H.
Wainberg, Zev A.
Kher, Uma
Shah, Sukrut
Kang, S. Peter
Tabernero, Josep
[J]. JAMA ONCOLOGY, 2020, 6 (10) : 1571 - 1580
[6] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Bang, Yung-Jue
Kang, Yoon-Koo
Catenacci, Daniel V.
Muro, Kei
Fuchs, Charles S.
Geva, Ravit
Hara, Hiroki
Golan, Talia
Garrido, Marcelo
Jalal, Shadia I.
Borg, Christophe
Doi, Toshihiko
Yoon, Harry H.
Savage, Mary J.
Wang, Jiangdian
Dalal, Rita P.
Shah, Sukrut
Wainberg, Zev A.
Chung, Hyun Cheol
[J]. GASTRIC CANCER, 2019, 22 (04) : 828 - 837
[7] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Yung-Jue Bang
Yoon-Koo Kang
Daniel V. Catenacci
Kei Muro
Charles S. Fuchs
Ravit Geva
Hiroki Hara
Talia Golan
Marcelo Garrido
Shadia I. Jalal
Christophe Borg
Toshihiko Doi
Harry H. Yoon
Mary J. Savage
Jiangdian Wang
Rita P. Dalal
Sukrut Shah
Zev A. Wainberg
Hyun Cheol Chung
[J]. Gastric Cancer, 2019, 22 : 828 - 837
[8] Pembrolizumab plus chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study
Chung, H. C.
Bang, Y-J.
Tabernero, J.
Van Cutsem, E.
Fuchs, C. S.
Wyrwicz, L.
Lee, K-W.
Kudaba, I.
Garrido, M.
Castro, H.
Mansoor, W.
Braghiroli, M. I.
Goekkurt, E.
Chao, J.
Wainberg, Z. A.
Kher, U.
Shah, S.
Shitara, K.
[J]. ANNALS OF ONCOLOGY, 2019, 30
[9] Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062
Satake, Hironaga
Lee, Keun-Wook
Chung, Hyun Cheol
Lee, Jeeyun
Yamaguchi, Kensei
Chen, Jen-Shi
Yoshikawa, Takaki
Amagai, Kenji
Yeh, Kun-Huei
Goto, Masahiro
Chao, Yee
Lam, Ka-On
Han, Shi Rong
Shiratori, Shinichi
Shah, Sukrut
Shitara, Kohei
[J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (03) : 221 - 229
[10] Association of Tumor Mutational Burden with Efficacy of Pembrolizumab plus Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
Lee, Keun-Wook
Van Cutsem, Eric
Bang, Yung-Jue
Fuchs, Charles S.
Kudaba, Iveta
Garrido, Marcelo
Chung, Hyun Cheol
Lee, Jeeyun
Castro, Hugo R.
Chao, Joseph
Wainberg, Zev A.
Cao, Z. Alexander
Aurora-Garg, Deepti
Kobie, Julie
Cristescu, Razvan
Bhagia, Pooja
Shah, Sukrut
Tabernero, Josep
Shitara, Kohei
Wyrwicz, Lucjan
[J]. CLINICAL CANCER RESEARCH, 2022, 28 (16) : 3489 - 3498

← 1 2 3 4 5 →